XML 45 R29.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Supplemental data | 9 Months Ended
--- | ---
Sep. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract] |
Supplemental data |
22. | Supplemental data
The following information is presented as supplemental data as required by the indentures governing the Company’s senior notes. Condensed Consolidating Statements of Income
|  |  |  |  |  |  |  |  |  |  |  |  |  | Company and |
|  | Consolidated |  |  | Physician |  |  | Unrestricted |  |  | Restricted |
For the nine months ended September 30, 2016 |  | Total |  |  | Groups |  |  | Subsidiaries |  |  | Subsidiaries(1) |
Patient service operating revenues |  | $ | 7,678,053 |  |  | $ | 287,544 |  |  | $ | — |  |  | $ | 7,390,509 |
Less: Provision for uncollectible accounts |  |  | (336,188 | ) |  |  | (9,178 | ) |  |  | — |  |  |  | (327,010 | )
Net patient service operating revenues |  |  | 7,341,865 |  |  |  | 278,366 |  |  |  | — |  |  |  | 7,063,499 |
Capitated revenues |  |  | 2,654,163 |  |  |  | 1,186,001 |  |  |  | — |  |  |  | 1,468,162 |
Other revenues |  |  | 1,033,335 |  |  |  | 53,124 |  |  |  | — |  |  |  | 980,211 |
Total net operating revenues |  |  | 11,029,363 |  |  |  | 1,517,491 |  |  |  | — |  |  |  | 9,511,872 |
Operating expenses |  |  | 9,516,248 |  |  |  | 1,513,569 |  |  |  | (129 | ) |  |  | 8,002,808 |
Operating income |  |  | 1,513,115 |  |  |  | 3,922 |  |  |  | 129 |  |  |  | 1,509,064 |
Debt expense, including refinancing charges |  |  | (310,359 | ) |  |  | (9,347 | ) |  |  | — |  |  |  | (301,012 | )
Other income |  |  | 8,067 |  |  |  | 322 |  |  |  | — |  |  |  | 7,745 |
Income tax expense |  |  | 366,011 |  |  |  | 10,442 |  |  |  | 52 |  |  |  | 355,517 |
Net income (loss) |  |  | 844,812 |  |  |  | (15,545 | ) |  |  | 77 |  |  |  | 860,280 |
Less: Net income attributable to noncontrolling interests |  |  | (122,664 | ) |  |  | — |  |  |  | — |  |  |  | (122,664 | )
Net income (loss) attributable to DaVita Inc. |  | $ | 722,148 |  |  | $ | (15,545 | ) |  | $ | 77 |  |  | $ | 737,616 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Comprehensive Income
|  |  |  |  |  |  |  |  |  | Company and |
|  | Consolidated |  |  | Physician |  |  | Unrestricted |  |  | Restricted |
For the nine months ended September 30, 2016 |  | Total |  |  | Groups |  |  | Subsidiaries |  |  | Subsidiaries(1) |
Net income (loss) |  | $ | 844,812 |  |  | $ | (15,545 | ) |  | $ | 77 |  |  | $ | 860,280 |
Other comprehensive loss |  |  | 7,807 |  |  |  | — |  |  |  | — |  |  |  | 7,807 |
Total comprehensive income (loss) |  |  | 852,619 |  |  |  | (15,545 | ) |  |  | 77 |  |  |  | 868,087 |
Less: comprehensive income attributable to the noncontrolling interests |  |  | (122,871 | ) |  |  | — |  |  |  | — |  |  |  | (122,871 | )
Comprehensive income (loss) attributable to DaVita Inc. |  | $ | 729,748 |  |  | $ | (15,545 | ) |  | $ | 77 |  |  | $ | 745,216 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Balance Sheets
|  |  |  |  |  |  |  |  |  |  |  |  |  | Company and |
|  | Consolidated |  |  | Physician |  |  | Unrestricted |  |  | Restricted |
As of September 30, 2016 |  | Total |  |  | Groups |  |  | Subsidiaries |  |  | Subsidiaries(1) |
Cash and cash equivalents |  | $ | 913,496 |  |  | $ | 104,636 |  |  | $ | — |  |  | $ | 808,860 |
Accounts receivable, net |  |  | 1,850,425 |  |  |  | 195,488 |  |  |  | — |  |  |  | 1,654,937 |
Other current assets |  |  | 1,497,438 |  |  |  | 18,419 |  |  |  | — |  |  |  | 1,479,019 |
Total current assets |  |  | 4,261,359 |  |  |  | 318,543 |  |  |  | — |  |  |  | 3,942,816 |
Property and equipment, net |  |  | 3,044,988 |  |  |  | 1,417 |  |  |  | — |  |  |  | 3,043,571 |
Amortizable intangibles, net |  |  | 1,576,157 |  |  |  | 5,141 |  |  |  | — |  |  |  | 1,571,016 |
Other long-term assets |  |  | 660,153 |  |  |  | 77,681 |  |  |  | 2,696 |  |  |  | 579,776 |
Goodwill |  |  | 9,382,996 |  |  |  | 16,405 |  |  |  | — |  |  |  | 9,366,591 |
Total assets |  | $ | 18,925,653 |  |  | $ | 419,187 |  |  | $ | 2,696 |  |  | $ | 18,503,770 |
Current liabilities |  | $ | 2,639,469 |  |  | $ | 229,515 |  |  | $ | — |  |  | $ | 2,409,954 |
Payables to parent |  |  | — |  |  |  | 86,335 |  |  |  | 2,696 |  |  |  | (89,031 | )
Long-term debt and other long-term liabilities |  |  | 10,195,049 |  |  |  | 50,099 |  |  |  | — |  |  |  | 10,144,950 |
Noncontrolling interests subject to put provisions |  |  | 971,744 |  |  |  | — |  |  |  | — |  |  |  | 971,744 |
Total DaVita Inc. shareholders’ equity |  |  | 4,911,746 |  |  |  | 53,238 |  |  |  | — |  |  |  | 4,858,508 |
Noncontrolling interests not subject to put provisions |  |  | 207,645 |  |  |  | — |  |  |  | — |  |  |  | 207,645 |
Shareholders’ equity |  |  | 5,119,391 |  |  |  | 53,238 |  |  |  | — |  |  |  | 5,066,153 |
Total liabilities and shareholder’s equity |  | $ | 18,925,653 |  |  | $ | 419,187 |  |  | $ | 2,696 |  |  | $ | 18,503,770 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Cash Flows
|  |  |  |  |  |  |  |  |  |  |  |  |  | Company and |
|  | Consolidated |  |  | Physician |  |  | Unrestricted |  |  | Restricted |
For the nine months ended September 30, 2016 |  | Total |  |  | Groups |  |  | Subsidiaries |  |  | Subsidiaries(1) |
Cash flows from operating activities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net income (loss) |  | $ | 844,812 |  |  | $ | (15,545 | ) |  | $ | 77 |  |  | $ | 860,280 |
Changes in operating and intercompany assets and liabilities and non-cash items included in net income |  |  | 636,450 |  |  |  | 152,461 |  |  |  | (77 | ) |  |  | 484,066 |
Net cash provided by operating activities |  |  | 1,481,262 |  |  |  | 136,916 |  |  |  | — |  |  |  | 1,344,346 |
Cash flows from investing activities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additions of property and equipment |  |  | (575,243 | ) |  |  | (592 | ) |  |  | — |  |  |  | (574,651 | )
Acquisitions and divestitures, net |  |  | (497,331 | ) |  |  | — |  |  |  | — |  |  |  | (497,331 | )
Proceeds from discontinued operations |  |  | 18,991 |  |  |  | — |  |  |  | — |  |  |  | 18,991 |
Investments and other items |  |  | (203,659 | ) |  |  | (2,124 | ) |  |  | — |  |  |  | (201,535 | )
Net cash used in investing activities |  |  | (1,257,242 | ) |  |  | (2,716 | ) |  |  | — |  |  |  | (1,254,526 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Long-term debt |  |  | (98,724 | ) |  |  | (4 | ) |  |  | — |  |  |  | (98,720 | )
Intercompany |  |  | — |  |  |  | (117,805 | ) |  |  | — |  |  |  | 117,805 |
Other items |  |  | (709,252 | ) |  |  | — |  |  |  | — |  |  |  | (709,252 | )
Net cash used in by financing activities |  |  | (807,976 | ) |  |  | (117,809 | ) |  |  | — |  |  |  | (690,167 | )
Effect of exchange rate changes on cash |  |  | (1,664 | ) |  |  | — |  |  |  | — |  |  |  | (1,664 | )
Net decrease in cash |  |  | (585,620 | ) |  |  | 16,391 |  |  |  | — |  |  |  | (602,011 | )
Cash and cash equivalents at beginning of period |  |  | 1,499,116 |  |  |  | 88,245 |  |  |  | — |  |  |  | 1,410,871 |
Cash and cash equivalents at end of period |  | $ | 913,496 |  |  | $ | 104,636 |  |  | $ | — |  |  | $ | 808,860 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration